Arginine at position 74 of the HLA-DR β1 chain is associated with Graves' disease

被引:113
作者
Ban, Y
Davies, TF
Greenberg, DA
Concepcion, ES
Osman, R
Oashi, T
Tomer, Y
机构
[1] Mt Sinai Sch Med, Div Endocrinol Diabet & Bone Dis, Dept Med, New York, NY 10029 USA
[2] Columbia Univ, Dept Biostat, Div Stat Genet, New York, NY 10032 USA
[3] Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA
关键词
Graves' disease; HLA; association; gene; autoimmunity;
D O I
10.1038/sj.gene.6364059
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Graves' disease (GD) is associated with HLA-DR3 (DRB1* 03) in Caucasians, but the exact amino-acid sequence in the DRbeta1 chain conferring susceptibility to GD is unknown. Therefore, the aim of our study was to identify the critical sequence among the HLA-DRB1 amino-acid residues occupying the peptide-binding pocket, which conferred susceptibility to GD. We sequenced the HLA-DRB1 locus in 208 Caucasian GD patients and 149 Caucasian controls. Sequence analysis showed an increased frequency of DR beta-Arg-74 in GD patients compared to controls (41.8 and 13.4%, respectively; P = 2.3 x 10(-8), OR = 4.6). Moreover, subset analyses showed that DR beta-Arg-74 was also significantly more frequent in the HLA-DR3 negative GD patients than in controls (7.6 vs 0.8%, P = 0.02, OR = 10.5), suggesting that the association with DR beta-Arg-74 is independent of the association with HLA-DR3. Structural modeling studies demonstrated that the change at position 74 from the neutral amino acids Ala or Gln to the positively charged amino-acid Arg significantly modifies the three-dimensional structure of the DR peptide-binding pocket. Our results suggested that structural heterogeneity of the DR beta-chain peptide-binding pocket P4 at residue 74 predispose some at risk individuals to GD.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 44 条
[11]   THE STRUCTURE OF AN INTERMEDIATE IN CLASS-II MHC MATURATION - CLIP BOUND TO HLA-DR3 [J].
GHOSH, P ;
AMAYA, M ;
MELLINS, E ;
WILEY, DC .
NATURE, 1995, 378 (6556) :457-462
[12]  
HAWKINS BR, 1985, ACTA ENDOCRINOL-COP, V110, P66, DOI 10.1530/acta.0.1100066
[13]   Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: Replication using a population case control and family-based study [J].
Heward, JM ;
Allahabadia, A ;
Daykin, J ;
Carr-Smith, J ;
Daly, A ;
Armitage, M ;
Dodson, PM ;
Sheppard, MC ;
Barnett, AH ;
Franklyn, JA ;
Gough, SCL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (10) :3394-3397
[14]   Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994):: National Health and Nutrition Examination Survey (NHANES III) [J].
Hollowell, JG ;
Staehling, NW ;
Flanders, WD ;
Hannon, WH ;
Gunter, EW ;
Spencer, CA ;
Braverman, LE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :489-499
[15]   Epidemiology and estimated population burden of selected autoimmune diseases in the United States [J].
Jacobson, DL ;
Gange, SJ ;
Rose, NR ;
Graham, NMH .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 84 (03) :223-243
[16]   A C/T polymorphism in the 5′-untranslated region of the CD40 gene is associated with Graves' disease in Koreans [J].
Kim, TY ;
Park, YJ ;
Hwang, JK ;
Song, JY ;
Park, KS ;
Cho, BY ;
Park, DJ .
THYROID, 2003, 13 (10) :919-925
[17]   Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type I diabetes [J].
Lee, KH ;
Wucherpfennig, KW ;
Wiley, DC .
NATURE IMMUNOLOGY, 2001, 2 (06) :501-507
[18]   GENETIC-FACTORS IN AUTOIMMUNE THYROID-DISEASE ANALYZED BY RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISMS OF CANDIDATE GENES [J].
MANGKLABRUKS, A ;
COX, N ;
DEGROOT, LJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1991, 73 (02) :236-244
[19]  
Marsh S G, 2001, Hum Immunol, V62, P419, DOI 10.1016/S0198-8859(01)00229-4
[20]   Relationship between the number and impact of stressful life events and the onset of Graves' disease and toxic nodular goitre [J].
Matos-Santos, A ;
Nobre, EL ;
Costa, JGE ;
Nogueira, PJ ;
Macedo, A ;
Galvao-Teles, A ;
de Castro, JJ .
CLINICAL ENDOCRINOLOGY, 2001, 55 (01) :15-19